The Impact Centre is working with SYNG Pharmaceuticals to develop a new non-invasive diagnostic test for endometriosis, an immunologic condition affecting one in ten women.

Endometriosis is caused when the endometrium, the layer of tissue that normally covers the inside of the uterus, grows outside of the uterus. Women with the condition suffer daily debilitating pain, abnormal bleeding and infertility, all of which significantly impacts their quality of life. Unfortunately, the condition remains misdiagnosed and misunderstood with few effective treatment options.

SYNG Pharmaceuticals, an early-stage biotechnology company, is devoted to developing a first-in-class noninvasive diagnostic test and therapeutic for endometriosis. The company has engineered proprietary antibodies for a newly discovered potential biomarker for endometriosis and needed an experienced partner to help develop a biosensor for a rapid diagnostic test.

Funded through NSERC Engage and OCE Voucher for Innovation and Productivity (VIP), the project will draw on the Impact Centre’s expertise in biomaterials, nanotechnology, and surface chemistry. Specifically, Prof. Cynthia Goh’s research group, which previously developed a diffractive optics-based diagnostic device and founded Axela Biosystems, will develop a point of care, easy to use prototype diagnostic based on a lateral flow technology.

This collaboration will enable SYNG Pharmaceuticals to accelerate the development of a new diagnostic device for endometriosis, which will assist in developing novel therapeutics for this significant unmet medical need.

“The Impact Centre has unique multi-disciplinary abilities and resources under one roof, making it an ideal research partner. We are excited that Ontario Centres of Excellence and NSERC Engage program is supporting our revolutionary research program,” said Dr. Vinay Singh, CEO of SYNG Pharmaceuticals.

Learn more about how the Impact Centre can accelerate your product development.

Share This